Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
53%) than with lower doses, placebo (8/98
United States Legal Status and Compounded Peptide Considerations FDAs May 2026 bulk-substance document lists GHK-Cu except for injectable routes of administration as a 503A category 1 substance under evaluation and says FDA intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 about potential inclusion on the 503A bulks list [19]
The 2025 Zdrada-Nowak review in International Journal of Molecular Sciences confirmed the clinical evidence for AH-8 in wrinkle reduction, elasticity, and hydration, but flagged the specific limitation that low intrinsic skin penetration is the main efficacy ceiling for topical use [12]
However, during the writing of this article, we discovered the need for more research to understand the interplay between the nervous system and gastrointestinal hormones, unexplored GLP-1 or GIP receptors, genetic background, endocrine cells, and the composition of dietary intake
